STOCK TITAN

IRIDEX (IRIX) CFO Romeo Dizon purchases 1,500 shares of company stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, bought company stock in the open market. On 02/12/2026, he purchased 1,500 shares of IRIDEX common stock at a price of $1.43 per share in a direct transaction.

Following this purchase, Dizon directly beneficially owned 117,690 shares of IRIDEX common stock. The filing records this as an open-market purchase under the standard insider transaction reporting rules.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/12/2026 P 1,500 A $1.43 117,690 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 02/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRIDEX (IRIX) report for its CFO?

IRIDEX reported that Chief Financial Officer Romeo R. Dizon bought 1,500 shares of common stock. The open-market purchase occurred on February 12, 2026, at $1.43 per share, and was reported as a direct ownership transaction on Form 4.

How many IRIDEX (IRIX) shares does the CFO own after this Form 4?

After the reported transaction, CFO Romeo R. Dizon beneficially owned 117,690 shares of IRIDEX common stock. This figure reflects his holdings following the February 12, 2026 open-market purchase of 1,500 shares at a price of $1.43 per share.

What was the price and size of the IRIDEX (IRIX) CFO’s stock purchase?

The CFO bought 1,500 IRIDEX common shares at $1.43 per share. This open-market transaction was recorded as a direct acquisition on February 12, 2026 and reported under transaction code “P” on Form 4.

What does transaction code "P" mean in the IRIDEX (IRIX) Form 4 filing?

Transaction code “P” indicates a purchase in the open market or a private transaction. In this case, it shows IRIDEX CFO Romeo R. Dizon acquired 1,500 common shares on February 12, 2026 at a price of $1.43 per share.

Is the IRIDEX (IRIX) CFO’s February 2026 share purchase direct or indirect ownership?

The reported IRIDEX transaction reflects direct ownership by the CFO. The Form 4 lists the 1,500 purchased shares as directly held, and shows total directly beneficially owned shares of 117,690 following the February 12, 2026 open-market purchase.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

23.72M
11.94M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW